Agios Pharmaceuticals Inc. (AGIO)

78.10
0.40 0.51
NASDAQ : Health Technology
Prev Close 77.70
Open 76.96
Day Low/High 76.25 / 79.96
52 Wk Low/High 45.11 / 82.96
Volume 237.96K
Avg Volume 563.60K
Exchange NASDAQ
Shares Outstanding 55.71M
Market Cap 4.29B
EPS -6.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.

(Graphic: Business Wire)

(Graphic: Business Wire)

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that IDHIFA ® (enasidenib) was granted approval from the U.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP Announces Corporate Governance Investigation Of Agios Pharmaceuticals Inc. - AGIO

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Agios Pharmaceuticals Inc.

Updated Data From Phase 1 Trial Of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses And Duration Of Response In Patients With Relapsed Or Refractory AML And An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral...

TheStreet Quant Rating: D (Sell)